What leadership changes did Australian Clinical Labs (ASX:ACL) announce?

Australian Clinical Labs announced that Greg Horan has been appointed as its new Group CEO and Executive Director. He will join the company as Group CEO-elect on 1 June 2026, officially taking over full executive responsibilities on 31 August 2026.

Who is incoming CEO Greg Horan, and what is his professional background?

Greg Horan is an experienced executive who most recently served as the CEO of Healthscope, where he managed 43 hospitals, 20,000 employees, and 5,000 visiting medical officers through post-pandemic industry changes.

Why does this executive transition matter for Australian Clinical Labs (ASX:ACL) shareholders?

CEO transitions introduce execution risk, but replacing a long-standing leader with an established healthcare executive helps maintain institutional stability. Horan’s experience running a major hospital network suggests he understands complex clinical operations and volume-driven healthcare models.

How might the Australian Clinical Labs (ASX:ACL) share price react in the short term?

The short-term share price reaction is typically neutral to mildly positive when a company replaces a veteran CEO with a proven industry insider rather than leaving a prolonged leadership vacuum. Because outgoing CEO Melinda McGrath has endorsed Horan’s commercial acumen, the market is likely to view the transition as orderly.

What are the main bull points for Australian Clinical Labs (ASX:ACL) following this announcement?

The primary bull case is that Horan brings fresh corporate experience from Healthscope, having successfully steered a major private hospital operator through complex post-pandemic market dynamics.

What are the key bear points and risks for Australian Clinical Labs (ASX:ACL) investors to watch?

The main bear point is the loss of Melinda McGrath, whose ten-year tenure provided a decade of stable corporate narrative and successful operational execution. Any major leadership change carries the risk of a strategy pivot, management churn, or temporary integration friction during the transition period.

Image for illustrative purposes only. Not a real photo.

Greg Horan appointed CEO of Australian Clinical Labs

Written by Isaac FrancisPublished May. 28 2026Last Updated May. 28 2026

Australian Clinical Labs (ASX:ACL) appointed Greg Horan as its new Group CEO and executive director.

Horan is scheduled to join the company on June 1 as group CEO-elect, with his full executive role taking effect on Aug. 31.

The transition occurs as the current group CEO and executive director, Melinda McGrath, prepares to step down from her position after a highly successful ten-year tenure.

Horan joins ACL with an extensive professional background, having most recently served as the CEO of Healthscope.

In that capacity, he managed the business through significant post-pandemic industry changes, directing operations across 43 hospitals with 20,000 employees and 5,000 visiting medical officers.

His 25-year career began in the mining sector before transitioning into private equity with Brookfield Capital Partners, establishing a strong reputation for operational execution, accountability, and team empowerment.

ACL Board Chair Stephen Roche welcomed the appointment, emphasising that Mr Horan’s deep experience in managing complex healthcare organisations positions him perfectly to guide the company through its next phase of strategic growth.

Outgoing CEO Melinda McGrath also expressed confidence in his leadership, praising his commercial acumen.

Horan noted that he looks forward to collaborating with the executive team to sustain ACL's strong clinical presence and market-leading momentum across Australia's healthcare landscape.